In this study, we evaluated the impact of RC48 on HER2-positive colon cancer cells both in vitro and in vivo and discovered that RC48 was able to significantly suppress HER2-positive colon cancer and enhance the effectiveness of anti-PD-1 therapy by activating the cGAS-STING pathway. This evidence concerns the gene ERBB2 and malignant colon neoplasm.